CLEVELAND, February 23, 2024 — The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood transplantation. The NCBN aims to increase accessibility to life-saving cord blood transplantation for patients with hematologic malignancies in US Transplant Centers as well as optimize cord blood transplant practices. [Read more…]
RESILIÉLLE COSMETICS LLC Unveils Exosome Results of First-Ever 100-Person Trial on Age Zero Exosome Cosmetic Serum Applied Topically Post Microneedling
Eight Medical Spas Participate in Nationwide Pioneering Study
Rochester NY, February 13, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare solutions, proudly announces the successful completion of the world’s first 100-person microneedling-plus-exosome trial, conducted at eight renowned medspas across the country. The clinicians participated in the trial in order to analyze what is the most effective amount of RESILIÉLLE Age Zero ExosomeTM topical serum to be applied after facial microneedling. [Read more…]
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2024
Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell
Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:
- Cell line generation for bio-production and bioassays
- Patient-relevant cell models for personalized medicine
- Physiologically predictive animal and cellular models of human disease
Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.
ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]
AVANT BIO Emerges as a Leading Equity Firm in Life Sciences, Tech Bio, and HealthTech
NEW YORK — AVANT BIO LLC, a pioneering early stage and growth equity firm, announces its official launch, positioning itself at the forefront of today’s transformative landscape in life sciences, tech bio, and healthtech industries. The Firm’s investments align with the convergence of groundbreaking technologies and an enhanced understanding of biology, creating a powerful synergy poised for breakthrough advancements in the future. [Read more…]
- « Previous Page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- …
- 334
- Next Page »